SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments

被引:93
作者
Joyce, Peter I. [1 ]
Fratta, Pietro [2 ]
Fisher, Elizabeth M. C. [2 ]
Acevedo-Arozena, Abraham [1 ]
机构
[1] MRC Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England
[2] UCL Inst Neurol, London WC1N 3BG, England
基金
英国医学研究理事会;
关键词
MOTOR-NEURON DEGENERATION; MUTANT SUPEROXIDE-DISMUTASE; WILD-TYPE SOD1; FRONTOTEMPORAL LOBAR DEGENERATION; ALS-LINKED SOD1; SPINAL MUSCULAR-ATROPHY; SOD1(G93A) MOUSE MODEL; DNA-BINDING PROTEIN; TRANSGENIC MICE; GROWTH-FACTOR;
D O I
10.1007/s00335-011-9339-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with no cure. Breakthroughs in understanding ALS pathogenesis came with the discovery of dominant mutations in the superoxide dismutase 1 gene (SOD1) and other genes, including the gene encoding transactivating response element DNA binding protein-43 (TDP-43). This has led to the creation of animal models to further our understanding of the disease and identify a number of ALS-causing mechanisms, including mitochondrial dysfunction, protein misfolding and aggregation, oxidative damage, neuronal excitotoxicity, non-cell autonomous effects and neuroinflammation, axonal transport defects, neurotrophin depletion, effects from extracellular mutant SOD1, and aberrant RNA processing. Here we summarise the SOD1 and TDP-43 animal models created to date, report on recent findings supporting the potential mechanisms of ALS pathogenesis, and correlate this understanding with current developments in the clinic.
引用
收藏
页码:420 / 448
页数:29
相关论文
共 231 条
[1]   Neuronal over-expression of chromogranin A accelerates disease onset in a mouse model of ALS [J].
Abou Ezzi, Samer ;
Lariviere, Roxanne ;
Urushitani, Makoto ;
Julien, Jean-Pierre .
JOURNAL OF NEUROCHEMISTRY, 2010, 115 (05) :1102-1111
[2]   Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial [J].
Aggarwal, Swati P. ;
Zinman, Lorne ;
Simpson, Elizabeth ;
McKinley, Jane ;
Jackson, Katherine E. ;
Pinto, Hanika ;
Kaufman, Petra ;
Conwit, Robin A. ;
Schoenfeld, David ;
Shefner, Jeremy ;
Cudkowicz, Merit .
LANCET NEUROLOGY, 2010, 9 (05) :481-488
[3]   Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS [J].
Amoiridis, Georgios ;
Tsimoulis, Dimitrios ;
Ameridou, Ioanna .
NEUROLOGY, 2008, 71 (10) :779-779
[4]   Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene [J].
Andersen, Peter M. .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2006, 6 (01) :37-46
[5]   RNA granules [J].
Anderson, P ;
Kedersha, N .
JOURNAL OF CELL BIOLOGY, 2006, 172 (06) :803-808
[6]   Neurotoxic effects of TDP-43 overexpression in C-elegans [J].
Ash, Peter E. A. ;
Zhang, Yong-Jie ;
Roberts, Christine M. ;
Saldi, Tassa ;
Hutter, Harald ;
Buratti, Emanuele ;
Petrucelli, Leonard ;
Link, Christopher D. .
HUMAN MOLECULAR GENETICS, 2010, 19 (16) :3206-3218
[7]  
Awano T, 2009, P NATL ACAD SCI USA, V106, P2794, DOI [10.1073/pnas.0812297106, 10.1073/pnas.0905845106]
[8]   Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target [J].
Barber, Sian C. ;
Shaw, Pamela J. .
FREE RADICAL BIOLOGY AND MEDICINE, 2010, 48 (05) :629-641
[9]   Lost in translation: Treatment trials in the SOD1 mouse and in human ALS [J].
Benatar, Michael .
NEUROBIOLOGY OF DISEASE, 2007, 26 (01) :1-13
[10]   A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
BENSIMON, G ;
LACOMBLEZ, L ;
MEININGER, V ;
BOUCHE, P ;
DELWAIDE, C ;
COURATIER, P ;
BLIN, O ;
VIADER, F ;
PEYROSTPAUL, H ;
DAVID, J ;
MALOTEAUX, JM ;
HUGON, J ;
LATERRE, EC ;
RASCOL, A ;
CLANET, M ;
VALLAT, JM ;
DUMAS, A ;
SERRATRICE, G ;
LECHEVALLIER, B ;
PEUCH, AJ ;
NGUYEN, T ;
SHU, C ;
BASTIEN, P ;
PAPILLON, C ;
DURRLEMAN, S ;
LOUVEL, E ;
GUILLET, P ;
LEDOUX, L ;
ORVOENFRIJA, E ;
DIB, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :585-591